Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Yposkesi
Yposkesi
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Manufacturing
SK pharmteco subsidiary Yposkesi launches AAVelocity, a plug-and-play AAV platform
Designed to shorten turnaround on manufacturing AAVs, this new platform offers CGT developers more flexibility when producing viral vectors for clinical and commercial use
Ingredients
Yposkesi launches lentiviral vector production platform optimised for higher yields
Yposkesi, SK pharmteco’s clinical and commercial viral vector manufacturing arm for cell and gene therapies, has launched LentiSure
Research & Development
Yposkesi joins BioPhorum CGT consortium
Key challenges facing biopharmaceutical manufacturers include ensuring production efficiency while operating in a rapidly evolving regulatory environment
Finance
Yposkesi begins construction of second bioproduction site
Backed by majority shareholder SK Pharmteco, Yposkesi is investing $71m in the 5,000 sqm facility. The construction is projected to create approximately 80 jobs by 2023
Manufacturing
Axovant Gene Therapies chooses Yposkesi for viral vector production
The initial focus of the agreement will be on AAV-based gene therapies
Pharmaceutical
Yposkesi appoints Dr Fraser Wright as Senior Advisor
Subscribe now